These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 20478050)

  • 1. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.
    Biller BM; Colao A; Petersenn S; Bonert VS; Boscaro M
    BMC Endocr Disord; 2010 May; 10():10. PubMed ID: 20478050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Treatment of Cushing's Disease.
    Pivonello R; De Leo M; Cozzolino A; Colao A
    Endocr Rev; 2015 Aug; 36(4):385-486. PubMed ID: 26067718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.
    Fleseriu M; Petersenn S
    J Neurooncol; 2013 Aug; 114(1):1-11. PubMed ID: 23673515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical management of functioning pituitary adenoma: an update.
    Oki Y
    Neurol Med Chir (Tokyo); 2014; 54(12):958-65. PubMed ID: 25446388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of functional pituitary adenomas, trials and tribulations.
    Capatina C; Hanzu FA; Hinojosa-Amaya JM; Fleseriu M
    J Neurooncol; 2024 Jun; 168(2):197-213. PubMed ID: 38760632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future treatment strategies of aggressive pituitary tumors.
    Lamberts SW; Hofland LJ
    Pituitary; 2009; 12(3):261-4. PubMed ID: 19003539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment guidelines on Cushing's disease.
    Arnaldi G; Boscaro M
    F1000 Med Rep; 2009 Aug; 1():. PubMed ID: 20948716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of Cushing's disease: Overview and recent findings.
    Praw SS; Heaney AP
    Int J Gen Med; 2009 Dec; 2():209-17. PubMed ID: 20360906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on medical treatment for Cushing's disease.
    Cuevas-Ramos D; Lim DST; Fleseriu M
    Clin Diabetes Endocrinol; 2016; 2():16. PubMed ID: 28702250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
    Feelders RA; Fleseriu M; Kadioglu P; Bex M; González-Devia D; Boguszewski CL; Yavuz DG; Patino H; Pedroncelli AM; Maamari R; Chattopadhyay A; Biller BMK; Pivonello R
    Front Endocrinol (Lausanne); 2023; 14():1165681. PubMed ID: 37876540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of medical therapy for hormone-secreting Pituitary tumors on bone.
    Freda PU
    Pituitary; 2024 Jul; ():. PubMed ID: 38967763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis.
    Broersen LHA; Jha M; Biermasz NR; Pereira AM; Dekkers OM
    Pituitary; 2018 Dec; 21(6):631-641. PubMed ID: 29855779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: Opposite Tumoral and Hormonal Responses to Low-dose Pasireotide in Cushing's Disease.
    Serban AL; Zampetti B; Saladino A; Favero V; Chiodini I; Cozzi R
    Endocr Metab Immune Disord Drug Targets; 2024; 24(7):845-849. PubMed ID: 37937561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing's Syndrome.
    Pivonello R; Simeoli C; Paola ND; Larocca A; Crescenzo EM; Colao A
    touchREV Endocrinol; 2024 Apr; 20(1):43-51. PubMed ID: 38812665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternations of Blood Pressure Following Surgical or Drug Therapy for Prolactinomas.
    Cheng Y; Wang D; Tang H; Tong D; Zhao W; Lin S; Yao H; Lv W; Zhang X; Xue L; Shang H; Wu ZB
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Quality of Life in Patients with Pituitary Tumours.
    Crespo I; Santos A; Resmini E; Valassi E; Martínez-Momblán MA; Webb SM
    Eur Endocrinol; 2013 Mar; 9(1):32-36. PubMed ID: 30349608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).
    Giustina A; Uygur MM; Frara S; Barkan A; Biermasz NR; Chanson P; Freda P; Gadelha M; Haberbosch L; Kaiser UB; Lamberts S; Laws E; Nachtigall LB; Popovic V; Reincke M; van der Lely AJ; Wass JAH; Melmed S; Casanueva FF
    Pituitary; 2024 Jun; ():. PubMed ID: 38833044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic aspects of the treatment of pituitary gland tumours.
    Sowiński J; Sawicka N; Piątek K; Zybek A; Ruchała M
    Contemp Oncol (Pozn); 2013; 17(2):137-43. PubMed ID: 23788980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acromegaly management in the Nordic countries: A Delphi consensus survey.
    Arlien-Søborg MC; Dal J; Heck A; Stochholm K; Husted E; Feltoft CL; Rasmussen ÅK; Feldt-Rasmussen U; Andreassen M; Klose MC; Nielsen TL; Andersen MS; Christensen LL; Krogh J; Jarlov A; Bollerslev J; Nermoen I; Oksnes M; Dahlqvist P; Olsson T; Berinder K; Hoybye C; Petersson M; Akerman AK; Wahlberg J; Ekman B; Engstrom BE; Johannsson G; Ragnarsson O; Olsson D; Sigurjónsdóttir HÁ; Fougner SL; Matikainen N; Vehkavaara S; Metso S; Jaatinen P; Hämäläinen P; Rintamäki R; Yliaska I; Immonen H; Mäkimattila S; Cederberg-Tamminen H; Viukari M; Nevalainen P; Nuutila P; Schalin-Jäntti C; Burman P; Jørgensen JOL
    Clin Endocrinol (Oxf); 2024 Jun; ():. PubMed ID: 38865284
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.